What is Zacks Research’s Forecast for JAZZ Q1 Earnings?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) – Analysts at Zacks Research lifted their Q1 2025 earnings per share estimates for Jazz Pharmaceuticals in a research note issued on Tuesday, March 18th. Zacks Research analyst S. Ganoria now expects that the specialty pharmaceutical company will post earnings per share of $3.51 for the quarter, up from their prior estimate of $3.17. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.96 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals’ Q2 2025 earnings at $4.70 EPS, Q3 2025 earnings at $5.30 EPS, Q4 2025 earnings at $5.51 EPS, FY2025 earnings at $19.02 EPS, Q1 2026 earnings at $3.13 EPS, Q2 2026 earnings at $4.79 EPS, Q3 2026 earnings at $5.84 EPS, Q4 2026 earnings at $5.90 EPS, FY2026 earnings at $19.66 EPS and FY2027 earnings at $20.50 EPS.

A number of other analysts have also recently weighed in on JAZZ. HC Wainwright boosted their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. Truist Financial boosted their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Royal Bank of Canada decreased their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Piper Sandler reissued an “overweight” rating and issued a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. One research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $187.71.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $138.76 on Friday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a market capitalization of $8.43 billion, a PE ratio of 19.54, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $148.06. The company has a 50 day moving average price of $131.41 and a two-hundred day moving average price of $121.70.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. IFP Advisors Inc acquired a new stake in Jazz Pharmaceuticals during the fourth quarter worth $25,000. Quadrant Capital Group LLC lifted its holdings in shares of Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after acquiring an additional 101 shares during the period. Elequin Capital LP boosted its position in shares of Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after acquiring an additional 183 shares in the last quarter. CoreFirst Bank & Trust bought a new stake in Jazz Pharmaceuticals in the fourth quarter valued at about $28,000. Finally, Allianz SE bought a new stake in Jazz Pharmaceuticals in the fourth quarter valued at about $29,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CMO Robert Iannone sold 7,080 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the sale, the chief marketing officer now owns 82,024 shares in the company, valued at approximately $11,368,526.40. This trade represents a 7.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the transaction, the chief executive officer now owns 425,525 shares in the company, valued at $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock worth $4,022,825 in the last ninety days. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.